In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Validation of a novel high-sensitivity cardiac troponin i assay for early diagnosis of acute myocardial infarction

Session Cardiac troponins and other biomarkers in acute coronary syndromes

Speaker Jasper Boeddinghaus

Event : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Biomarkers
  • Session type : Rapid Fire Abstracts

Authors : J Boeddinghaus (Basel,CH), R Twerenbold (Basel,CH), T Nestelberger (Basel,CH), L Koechlin (Basel,CH), D Wussler (Basel,CH), K Wildi (Basel,CH), C Puelacher (Basel,CH), J Du Fay De Lavallaz (Basel,CH), M Rubini Gimenez (Basel,CH), JE Walter (Basel,CH), T Zimmermann (Basel,CH), O Miro (Barcelona,ES), FJ Martin-Sanchez (Madrid,ES), DI Keller (Zurich,CH), C Mueller (Basel,CH)

Authors:
J Boeddinghaus1 , R Twerenbold1 , T Nestelberger1 , L Koechlin1 , D Wussler1 , K Wildi1 , C Puelacher1 , J Du Fay De Lavallaz1 , M Rubini Gimenez1 , JE Walter1 , T Zimmermann1 , O Miro2 , FJ Martin-Sanchez3 , DI Keller4 , C Mueller1 , 1University Hospital Basel, Cardiovascular Research Institute Basel (CRIB) - Basel - Switzerland , 2Hospital Clinic de Barcelona, Emergency Department - Barcelona - Spain , 3Hospital Clinic San Carlos, Emergency Department - Madrid - Spain , 4University Hospital Zurich, Emergency Department - Zurich - Switzerland ,

On behalf: Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE)

Citation:

Background: The novel high-sensitivity cardiac troponin I (hs-cTnI)-Vitros assay was developed recently. Before its possible implementation into routine clinical care for triage of chest pain patients, its performance needs clinical validation.

Purpose: To clinically validate hs-cTnI-Vitros and to derive and validate an assay-specific 0/1h-algorithm following the European Society of Cardiology (ESC) recommendations.

Methods: In a prospective international multicentre study (12 centres in 5 European countries) we enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by two independent cardiologists including all clinical information including cardiac imaging twice: first, using serial hs-cTnT (Elecsys, primary analysis) and second, using hs-cTnI (Architect, secondary analysis) measurements in addition to the clinically used (hs)-cTn. Hs-cTnI-Vitros was measured at presentation and at 1h in a blinded fashion. Primary objective was direct comparison of diagnostic accuracy as quantified by the area under the receiver-operating-characteristic curve (AUC) of hs-cTnI-Vitros versus the two established hs-cTn assays (hs-cTnT-Elecsys, hs-cTnI-Architect). Secondary objectives included the derivation and validation of a hs-cTnI-Vitros specific 0/1h-algorithm.

Results: AMI was the adjudicated final diagnosis in 158/1231 (13%) patients. The AUC at presentation for hs-cTnI-Vitros was 0.95 (95%CI, 0.93-0.96), and significantly higher as hs-cTnT-Elecsys (0.94 [95%CI, 0.92-0.95; p=0.01]) and hs-cTnI-Architect (0.92 [95%CI, 0.90-0.94; p<0.001]). Applying the derived hs-cTnI-Vitros 0/1h-algorithm (derivation cohort n=519) to the validation cohort (n=520), 53% of patients were ruled-out (sensitivity 100% [95%CI, 98.6-100]), and 14% of patients were ruled-in (specificity 95.6% [95%CI, 93.4-97.2]). Patients ruled-out by the 0/1h-algorithm had a survival rate of 99.8% at 30-days and 98.7% at 2-years. Findings were confirmed in the secondary analyses using the adjudication including serial measurements of hs-cTnI (Architect).

Conclusions: The novel hs-cTnI-Vitros assay has even higher diagnostic accuracy as the current gold-standards hs-cTnT and hs-cTnI. The hs-cTnI-Vitros specific 0/1h-algorithms allows a safe rule-out and accurate rule-in of AMI in about 70% of patients within 1h after presentation to the ED.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are